X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Rhu-pGSN (gelsolin) is a recombinant protein which acts as IL-1β inhibitor. It is being evaluated for the treatment of acute respiratory distress syndrome.
Lead Product(s): Gelsolin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Rhu-pGSN
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
The funding will be used to advance recombinant human gelsolin (rhu-pGSN), a master regulator of the innate immune system, as a treatment for patients with for moderate-to-severe acute respiratory distress syndrome (ARDS).
Lead Product(s): Recombinant Human Gelsolin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Rhu-pGSN
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 16, 2023
Details:
Plasma gelsolin (pGSN) is a naturally occurring human protein that is an important component of the innate immune system. Plasma gelsolin is critically depleted in ARDS patients and has been shown to address both injurious and infectious inflammation.
Lead Product(s): Plasma Gelsolin Therapy
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Plasma Gelsolin Therapy
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
This funding will accelerate the expansion of BioAegis’ pipeline with new indications as the Company pursues its US Phase 2 program in severe pneumonia. The funds will also be used to further scale up manufacturing to support the development of secondary indications.
Lead Product(s): Recombinant Human Plasma Gelsolin
Therapeutic Area: Infections and Infectious Diseases Product Name: rhu-pGSN
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $22.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 22, 2022
Details:
Supplementing human gelsolin with recombinant form (rhu-pGSN) is host-directed approach to treating inflammatory and infectious diseases. Gelsolin, naturally occurring human protein that is abundant in healthy individuals, is a key component of body’s innate immune system.
Lead Product(s): Recombinant Human Plasma Gelsolin
Therapeutic Area: Infections and Infectious Diseases Product Name: rhu-pGSN
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2021
Details:
Recombinant human plasma gelsolin is an ancient, highly conserved human protein that is a highly abundant plasma protein in healthy individuals. Its role is to keep inflammation localized to the site of injury and to boost the body’s ability to clear pathogens.
Lead Product(s): Recombinant Human Plasma Gelsolin
Therapeutic Area: Infections and Infectious Diseases Product Name: Gelsolin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
Rhu-pGSN is a broad-acting threat-agnostic product that improves immune cell function at sites of injury by enhancing pathogen killing while also resolving inflammation.
Lead Product(s): Recombinant Human Plasma Gelsolin
Therapeutic Area: Infections and Infectious Diseases Product Name: rhu-pGSN
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 30, 2021
Details:
Supplementation with rhu-pGSN mitigates the observed vascular pathology. Gelsolin is non-immunosuppressive unlike current treatments to quell inflammatory cytokines.
Lead Product(s): Recombinant human plasma gelsolin
Therapeutic Area: Infections and Infectious Diseases Product Name: rhu-pGSN
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
Details:
The study assesses rhu-pGSN, and its ability to regulate the overactive inflammatory response often responsible for causing lung damage and death in COVID-19 patients.
Lead Product(s): Recombinant human plasma gelsolin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: rhu-pGSN
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2020
Details:
The compelling data from this NIH sponsored study show the potential of gelsolin to not only improve survival, but to diminish lung injury caused by virulent pneumonia.
Lead Product(s): Recombinant human plasma gelsolin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
